Bio-Techne appoints Dr. Judith Klimovsky to board, expands to 11 directors

BIO-TECHNE Corp

Dr. Klimovsky appointed independent director effective April 24, 2024; board temporarily expanded to 11 members (10 independent).
She will serve on the Science & Technology Committee.
Dr. Klimovsky is EVP & Chief Development Officer at Genmab; previously held senior roles at Novartis Oncology and Bristol-Myers Squibb.
Board also approved a one-year waiver of mandatory retirement policy for Dr. Roeland Nusse.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Judith Klimovsky

Director

TECH · BIO-TECHNE Corp

Effective: 2024-04-24
Filed: April 30, 2024, 7:59 PM ET

On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Judith Klimovsky was appointed as Director at BIO-TECHNE Corp.

Action: appointed
Role: Director

Exact text from the filing

On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director.

View on SEC.gov

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-006279

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.